Journal
ANNALS MEETING REPORTS 2013
Volume 1276, Issue -, Pages 26-36Publisher
BLACKWELL SCIENCE PUBL
DOI: 10.1111/j.1749-6632.2012.06811.x
Keywords
biosimilars; follow-on biologics; complex drug; NBCD
Categories
Funding
- Teva Pharmaceutical Industries LTD
Ask authors/readers for more resources
On March 9, 2012, the New York Academy of Sciences brought together experts representing a variety of perspectives-including academic, industrial, regulatory, as well as those from physicians and consumers-to discuss considerations for the non-biological complex drug (NBCD) regulatory approval pathway, given the emerging regulatory guidelines for biosimilars (follow-on biological complex drugs). Some of the organizers of the conference expressed their belief that NBCDs share a number of characteristic features with biologicals: the structure cannot be fully defined by the available (physicochemical) analytical tests, and quality assurance is based on in-depth knowledge, consistency, and control of the production process. However, their view on NBCDs was not universally accepted among the experts who participated in the conference. Plenary sessions addressed the most recent regulatory developments, experimental design, interchangeability, and immunogenicity issues for follow-on versions of complex drugs from the perspective of key audiences, including industry, regulatory agencies, physicians, and consumers. This report summarizes these various perspectives on NBCDs and the scientific and regulatory considerations associated with complex drug categories.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available